Inhibition of Mdm2–MdmX RING–RING interaction by MMRi6 and its analog MMRi64.
A new class of small-molecule compounds has been discovered that are good candidates for novel targeted therapies in leukemia and lymphoma Rx. They drive cancer cells to suicide, RPCI researchers report. “We are excited about the unique activities of these compounds and will continue to focus our research efforts on development of their clinical potential,” says Xinjiang Wang, PhD. “These compounds kill cancer cells, not just stop cancer cell growth temporarily. These types of agents offer the promise of therapeutic benefit.”
They demonstrated that the small-molecule MMRi compounds have an advantage over p53-activating agents in current use as cancer therapies...
Read More
Recent Comments